Literature DB >> 8455395

Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy.

D W Kimmel1, A J Schutt.   

Abstract

We report the fourth case of cerebral demyelinating disease associated with 5-fluorouracil and levamisole hydrochloride therapy for adenocarcinoma of the colon. The initial manifestations included subacute progressive decline in mental status, ataxia, dysarthria, and diplopia. Magnetic resonance imaging of the head demonstrated multifocal enhanced lesions in the white matter. The patient experienced improvement, without corticosteroid treatment, from 2 weeks to 4 months after cessation of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8455395     DOI: 10.1016/s0025-6196(12)60132-3

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  4 in total

1.  Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study.

Authors:  Jérémy T Campillo; Céline Eiden; Michel Boussinesq; Sébastien D S Pion; Jean-Luc Faillie; Cédric B Chesnais
Journal:  Br J Clin Pharmacol       Date:  2021-09-15       Impact factor: 3.716

2.  Adjuvant 5-fluorouracil plus levamisole in colon cancer: the plot thickens?

Authors:  J Cassidy
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

3.  Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.

Authors:  Ruolan Han; Yin M Yang; Joerg Dietrich; Anne Luebke; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2008-04-22

4.  Clinical features and magnetic resonance image analysis of 15 cases of demyelinating leukoencephalopathy induced by levamisole.

Authors:  Ruifang Yan; Qingwu Wu; Jipeng Ren; Hongkai Cui; Kaihua Zhai; Zhansheng Zhai; Qinghong Duan
Journal:  Exp Ther Med       Date:  2013-04-24       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.